Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue (2016 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Non-Current Deffered Revenue of $12.4 million for Q1 2026, down 1.86% on a QoQ basis from $12.6 million in Q4 2025, and little changed year-over-year from $12.4 million in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $12.4 million for Q1 2026.
- Quarterly Non-Current Deffered Revenue changed 0.3% year-over-year to $12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (changed 0.3% YoY) and the FY2025 annual result came in at $12.6 million, up 644.44% from the prior year.
- Non-Current Deffered Revenue was $12.4 million for Q1 2026 at Aurinia Pharmaceuticals, down from $12.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $12.6 million in Q4 2025 and bottomed at $1.7 million in Q4 2024.
- A 3-year average of $10.6 million and a median of $12.4 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2025 — Non-Current Deffered Revenue jumped 644.44% — and 2026, when it retreated 0.3%.
- Aurinia Pharmaceuticals' Non-Current Deffered Revenue stood at $1.7 million in 2024, then soared by 644.44% to $12.6 million in 2025, then slipped by 1.86% to $12.4 million in 2026.
- Business Quant data shows AUPH's Non-Current Deffered Revenue at $12.4 million in Q1 2026, $12.6 million in Q4 2025, and $12.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 12.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.41 Mn |
| Dec 31, 2025 | 12.65 Mn |
| Sep 30, 2025 | 12.25 Mn |
| Jun 30, 2025 | 12.35 Mn |
| Mar 31, 2025 | 12.45 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Dec 31, 2019 | 206,000.00 |
| Dec 31, 2018 | 324,000.00 |
| Dec 31, 2017 | 442,000.00 |
| Dec 31, 2016 | 560,000.00 |